Emergence of Institutional Antithrombotic Protocols for Coronavirus 2019
ISTH Academy. P. Cohoon K. 04/28/20; 297671
Kevin P. Cohoon
Contributions
Contributions
Journal Abstract
Abstract
The coronavirus infection (COVID‐19), first identified in December 2019 in Wuhan, China, is a major public health crisis with new infections increasing exponentially worldwide. COVID‐19 is an acute infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV2) and has contributed to significant morbidity and mortality, including the development of coagulopathy. Similar thrombotic and thromboembolic events have occurred during other viral outbreaks, including severe acute respiratory syndrome (SARS), Middle Eastern respiratory syndrome (MERS‐CoV), and influenza A H1N1.
The coronavirus infection (COVID‐19), first identified in December 2019 in Wuhan, China, is a major public health crisis with new infections increasing exponentially worldwide. COVID‐19 is an acute infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV2) and has contributed to significant morbidity and mortality, including the development of coagulopathy. Similar thrombotic and thromboembolic events have occurred during other viral outbreaks, including severe acute respiratory syndrome (SARS), Middle Eastern respiratory syndrome (MERS‐CoV), and influenza A H1N1.
{{ help_message }}
{{filter}}